Free Trial

ASLAN Pharmaceuticals (ASLN) Competitors

ASLAN Pharmaceuticals logo
$0.60 0.00 (0.00%)
As of 09/11/2025

ASLN vs. OGEN, ORGS, XBIO, INM, CMND, ONCO, JAGX, PWUP, TRIB, and REVB

Should you be buying ASLAN Pharmaceuticals stock or one of its competitors? The main competitors of ASLAN Pharmaceuticals include Oragenics (OGEN), Orgenesis (ORGS), Xenetic Biosciences (XBIO), InMed Pharmaceuticals (INM), Clearmind Medicine (CMND), Onconetix (ONCO), Jaguar Animal Health (JAGX), PowerUp Acquisition (PWUP), Trinity Biotech (TRIB), and Revelation Biosciences (REVB). These companies are all part of the "pharmaceutical products" industry.

ASLAN Pharmaceuticals vs. Its Competitors

Oragenics (NYSE:OGEN) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

Oragenics has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, ASLAN Pharmaceuticals has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500.

Oragenics' return on equity of -2,087.95% beat ASLAN Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
OragenicsN/A -2,087.95% -486.56%
ASLAN Pharmaceuticals N/A -8,454.87%-121.60%

Oragenics has higher earnings, but lower revenue than ASLAN Pharmaceuticals. Oragenics is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OragenicsN/AN/A-$20.66M-$21.42-0.06
ASLAN Pharmaceuticals$12M0.10-$44.22M-$21.92-0.03

18.7% of Oragenics shares are owned by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. 10.1% of Oragenics shares are owned by insiders. Comparatively, 4.7% of ASLAN Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Oragenics had 1 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 1 mentions for Oragenics and 0 mentions for ASLAN Pharmaceuticals. ASLAN Pharmaceuticals' average media sentiment score of 0.00 beat Oragenics' score of -1.00 indicating that ASLAN Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Oragenics Negative
ASLAN Pharmaceuticals Neutral

Summary

ASLAN Pharmaceuticals beats Oragenics on 6 of the 11 factors compared between the two stocks.

Get ASLAN Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ASLN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ASLN vs. The Competition

MetricASLAN PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.23M$934.71M$5.87B$10.14B
Dividend YieldN/A4.84%5.68%4.59%
P/E Ratio-0.031.1074.5225.93
Price / Sales0.1026.70548.33126.97
Price / CashN/A19.5637.5660.44
Price / Book-0.096.6912.166.29
Net Income-$44.22M-$4.50M$3.28B$270.77M
7 Day PerformanceN/A8.75%0.87%3.88%
1 Month PerformanceN/A9.50%4.96%4.88%
1 Year PerformanceN/A22.47%60.74%26.01%

ASLAN Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ASLN
ASLAN Pharmaceuticals
N/A$0.60
flat
N/AN/A$1.23M$12M-0.0330
OGEN
Oragenics
0.1993 of 5 stars
$1.17
-0.4%
N/A-91.9%$4.81MN/A-0.165Short Interest ↑
ORGS
Orgenesis
N/A$1.00
+525.0%
N/AN/A$4.80M$662K0.00150Gap Up
XBIO
Xenetic Biosciences
1.3148 of 5 stars
$3.05
-0.2%
N/A-6.5%$4.69M$2.50M-1.524Gap Down
INM
InMed Pharmaceuticals
1.295 of 5 stars
$2.25
+4.7%
N/A-61.9%$4.50M$4.60M-0.1910Positive News
Short Interest ↓
Gap Down
CMND
Clearmind Medicine
1.4252 of 5 stars
$1.03
+2.2%
N/A-22.7%$4.41MN/A-0.94N/AEarnings Report
Upcoming Earnings
Short Interest ↓
Gap Up
ONCO
Onconetix
0.9103 of 5 stars
$2.78
+3.7%
N/A-99.3%$4.30M$1.33M0.0012
JAGX
Jaguar Animal Health
1.6167 of 5 stars
$1.93
-2.5%
$60.00
+3,008.8%
-92.9%$4.19M$11.69M0.0050Short Interest ↑
PWUP
PowerUp Acquisition
N/A$0.51
0.0%
N/A-96.1%$3.97MN/A0.00N/AGap Up
High Trading Volume
TRIB
Trinity Biotech
1.7313 of 5 stars
$1.10
-1.8%
N/A-85.4%$3.97M$61.56M-0.08480Short Interest ↓
Gap Down
REVB
Revelation Biosciences
0.858 of 5 stars
$2.33
-17.4%
N/A-95.6%$3.96MN/A-0.0310News Coverage
Gap Down
High Trading Volume

Related Companies and Tools


This page (NASDAQ:ASLN) was last updated on 9/13/2025 by MarketBeat.com Staff
From Our Partners